Prostaglandin D2 metabolite is not a useful clinical indicator for assessing atopic dermatitis
Summary Prostaglandin D2(PGD2) plays an important role in atopic dermatitis (AD), and 11,15‐dioxo‐9α‐hydroxy‐2,3,4,5‐tetranorprostan‐1,20‐dioicacid (PGDM) is a major metabolite of PGD2. We investigated the relationship between urinary PGDM levels and severity of paediatric AD. In total, 31 patients with AD and 21 healthy controls (HCs) without AD were recruited, and urinary PGDM levels were measured. Of the 31 patients with AD, 14 were reassessed for urinary PGDM after topical steroid therapy. There was no difference in urinary PGDM levels between patients with AD and HCs. Although there was a significant positive correlation between the SCORing Atopic Dermatitis (SCORAD) index and the serum level of thymus and activation‐regulated chemokine (TARC), the urinary PGDM levels did not correlate with either SCORAD or serum TARC. Moreover, both SCORAD and serum TARC were significantly improved by topical steroid therapy; however, urinary PGDM levels were not changed. In conclusion, the level of urinary PGD2 metabolites in children with AD is substantially the same as that in HCs even if the disease is severe..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:46 |
|---|---|
| Enthalten in: |
Clinical and experimental dermatology - 46(2021), 1, Seite 130-134 |
| Beteiligte Personen: |
Inagaki, S. [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
Copyright © 2020 British Association of Dermatologists |
|---|
| Umfang: |
5 |
|---|
| doi: |
10.1111/ced.14393 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY003316718 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY003316718 | ||
| 003 | DE-627 | ||
| 005 | 20230307124946.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230213s2021 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/ced.14393 |2 doi | |
| 028 | 5 | 2 | |a CED_CED14393.xml |
| 035 | |a (DE-627)WLY003316718 | ||
| 035 | |a (WILEY)CED14393 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.93 |2 bkl | ||
| 100 | 1 | |a Inagaki, S. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prostaglandin D2 metabolite is not a useful clinical indicator for assessing atopic dermatitis |
| 264 | 1 | |c 2021 | |
| 300 | |a 5 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Copyright © 2020 British Association of Dermatologists | ||
| 520 | |a Summary Prostaglandin D2(PGD2) plays an important role in atopic dermatitis (AD), and 11,15‐dioxo‐9α‐hydroxy‐2,3,4,5‐tetranorprostan‐1,20‐dioicacid (PGDM) is a major metabolite of PGD2. We investigated the relationship between urinary PGDM levels and severity of paediatric AD. In total, 31 patients with AD and 21 healthy controls (HCs) without AD were recruited, and urinary PGDM levels were measured. Of the 31 patients with AD, 14 were reassessed for urinary PGDM after topical steroid therapy. There was no difference in urinary PGDM levels between patients with AD and HCs. Although there was a significant positive correlation between the SCORing Atopic Dermatitis (SCORAD) index and the serum level of thymus and activation‐regulated chemokine (TARC), the urinary PGDM levels did not correlate with either SCORAD or serum TARC. Moreover, both SCORAD and serum TARC were significantly improved by topical steroid therapy; however, urinary PGDM levels were not changed. In conclusion, the level of urinary PGD2 metabolites in children with AD is substantially the same as that in HCs even if the disease is severe. | ||
| 700 | 1 | |a Nakamura, T. |4 aut | |
| 700 | 1 | |a Hamasaki, Y. |4 aut | |
| 700 | 1 | |a Yamamoto‐Hanada, K. |4 aut | |
| 700 | 1 | |a Fukuie, T. |4 aut | |
| 700 | 1 | |a Narita, M. |4 aut | |
| 700 | 1 | |a Shimosawa, T. |4 aut | |
| 700 | 1 | |a Murata, T. |4 aut | |
| 700 | 1 | |a Ohya, Y. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and experimental dermatology |d Kettering : Oxford University Press, 1976 |g 46(2021), 1, Seite 130-134 |w (DE-627)WLY003310450 |w (DE-600)2004506-2 |x 13652230 |7 nnns |
| 773 | 1 | 8 | |g volume:46 |g year:2021 |g number:1 |g pages:130-134 |g extent:5 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 936 | b | k | |a 44.93 |q ASE |
| 951 | |a AR | ||
| 952 | |d 46 |j 2021 |e 1 |h 130-134 |g 5 | ||